Netscientific PLC (LON:NSCI)

Netscientific PLC (LON:NSCI)


Share Price
28.10 p
Change
0.2 (0.72 %)
Market Cap
£22.08 m
Proactive Investors - Run By Investors For Investors

Netscientific PLC

NetScientific Plc is a healthcare medical technology company that identifies, develops and commercializes research and technologies from leading universities, research institutes, and teaching hospitals globally. The Company is focused on: cardiovascular, liver, cancer, metabolic, and digital health.

EPIC: NSCI
Market: AIM:NSCI
52-week High/Low: 77.00p / 23.00p
Sector: Pharma & Biotech
Market Cap: 22.08M
Website: netscientific.net
col 3
col 4
col 5
col 6

Big picture - Why invest in Netscientific PLC


Netscientific PLC Snapshot

The business strategy is based on funding and building game-changing healthcare technology companies towards value inflection points and eventual exit including through a trade sale or public listing.

The Group sources opportunities from global institutions, leading technology incubators and its deep healthcare network. In the early stages of the company’s development the Group provides extensive management support including technical guidance, administrative support, legal, IP and commercial expertise.

As companies mature through key milestones the Group will recruit experienced industry leading CEOs to drive the next phase of growth, attract additional external capital and secure favourable exits.

The Group aims to grow the equity value of its interests in its portfolio companies through various key value inflection points such as clinical trials, regulatory approvals, collaborative funding arrangements, first revenues and follow-on growth. In turn, these value inflection points create exit or out-licensing opportunities for the Group through trade sales, licensing arrangements with larger market participants or IPOs.

Sir Richard Sykes, FRS
CHAIRMAN

Sir Richard Sykes, Non-Executive Chairman of the Group, joined NetScientific in 2008. Sir Richard spent thirty years working in the biotechnology and pharmaceutical industries, including at Glaxo plc (subsequently Glaxo Wellcome plc), where he served as Chairman and CEO from 1995 to 2000, and then GlaxoSmithKline plc, where he served as Chairman until 2002. Sir Richard was also Senior Independent Director and Chairman of Eurasian Natural Resources Corporation from 2007 to 2011, Chairman of NHS London from December 2000 to 2010, Rector of Imperial College from 2000 to 2008 and a Non-Executive Director of Rio Tinto plc from 1997 to 2007. He holds a BSc in Microbiology from the University of London, a PhD in Microbial Biochemistry from Bristol University and a DSc from the University of London.

In 1994, Sir Richard received a knighthood for services to the pharmaceutical industry. In 2004, he was awarded Honorary Citizenship of Singapore for his contribution to the development of the country’s biomedical sciences industry.

Currently, Sir Richard is a Fellow of the Royal Society and Academy of Medical Sciences, Imperial College London, Imperial College School of Medicine and King’s College London and an Honorary Fellow of the Royal Academy of Engineering, Royal Society of Chemistry, Royal Pharmaceutical Society, Royal College of Pathologists, Royal College of Physicians, the University of Wales and the University of Central Lancashire.

 

Francois Martelet, M.D.
CHIEF EXECUTIVE OFFICER


François Martelet, Chief Executive Officer, joined NetScientific Mid 2015.

He brings over 20 years of biopharma experience and a proven track record of shaping and developing businesses to deliver returns. He has broad experience in both large and small companies, deep knowledge of commercialisation and has proven managerial capabilities. In particular he successfully managed large P&L ($1+B) across large country organizations in senior level regional roles with full accountability of multiple product lines in primary care & specialty markets in Europe and Emerging markets.

Previously, François served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. During this period, sales revenues grew by 20+% and various new products were launched, including Oralair®, into ex-US markets. Before this, he was CEO at Topotarget A/S, a publicly traded European biotech company specialised in oncology therapeutics which he successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit.

Prior to this, François served as CEO of Avax Technologies Inc., a US biotech company specialised in therapeutic oncology vaccines. He has also held senior level commercial positions at Merck & Co, Inc. (VP & Global Franchise Head-Oncology), Novartis Pharma (SVP & Head of Central & Eastern Europe, Middle East and Africa), Schering-Plough and Eli Lilly.

François gained a Doctorate in Medicine and a Master’s Degree in Business from Dijon University, and holds a Degree in Legal Medicine from R. Descartes University School of Medicine, Paris. He is also a graduate of the Advanced General Management Program at INSEAD and attended senior executive courses at Harvard Business School.

François Martelet’s awards include the Pasteur Institute medal (1989) Knight of the French National Order Merit (2011) and the Knight of the Legion d’Honneur (2017) which is the highest decoration in France.

 

Barry Wilson
NON-EXECUTIVE DIRECTOR


Barry W Wilson, Non-Executive Director, joined the NetScientific Board in 2013. Barry is an international executive with 40+ years of experience in both the pharmaceutical and medical device industries.

He has served as the President of Medtronic International, President of Lederle International prior to its merger with Wyeth, and President of Bristol-Myers Squibb Europe. Additionally he had 9 international assignments with Pfizer. Barry serves on the Board of Welch Allyn and Anecova. He is a member of the Thematic Advisory Board of Lombard Odier Private Bank.

Barry advises several Venture Capital organisations/start-ups. He worked with DLJ Credit-Suisse Alternative Investments as their Healthcare Advisor and served on the boards of Mallinckrodt Inc, Bausch + Lomb (both NYSE) and Rezidor Hotel Group AB (Swedish stock exchange).

 

Professor Stephen Smith
NON-EXECUTIVE DIRECTOR


Professor Stephen Smith, Non-Executive Director, joined the NetScientific Board in 2016.

Stephen has held senior leadership roles in the NHS and academia. He has had a long and distinguished career as a clinician scientist, Head of Department, Dean and CEO.
His name is associated with the Medical Research Council, University of Cambridge, Imperial College, London and Imperial College Healthcare NHS Trust.

He was responsible for the largest merger in the NHS, the creation of the UK’s first Academic Health Science Centre in 2007. The merger brought together four London based NHS Trusts and ultimately led to the creation of Imperial College Healthcare NHS Trust, where Stephen served for four years as the first CEO. He also retained his position as Dean of the Faculty of Medicine at Imperial College, London and was responsible for facilitating the commercialisation of life sciences and healthcare.

During his career, Stephen has spun two companies out of Cambridge – Metris Therapeutics Ltd and GNI Group Ltd. GNI was established as a start up in Japan in 2001 and successfully achieved an Initial Public Offering (IPO) on the Tokyo Stock Exchange six years later.

Stephen has extensive non-executive experience serving on the Boards of the National Healthcare Group Singapore which developed integrated care through nine polyclinics. In Australia, he was on the Board of the Royal Melbourne Hospital and the Victorian Comprehensive Cancer Centre, a $1billion project to create a fully integrated cancer care facility that brings together an integrated research, service and education offering to four million patients in Victoria.

 

Ian Postlethwaite
CHIEF FINANCIAL OFFICER & COMPANY SECRETARY


Ian Postlethwaite, Chief Financial Officer, joined NetScientific in June 2016.
He brings over 14 years of biopharma experience and a proven track record of driving revenue growth and funding development programs. He has broad experience in both private and public companies; from start-ups to multi-nationals.

He was previously an Executive Director on the board of Allergy Therapeutics Plc. He joined Allergy in April 2002 as Finance Director whilst it was private company, initially performing a financial turnaround and then listing it two years later in 2004 on the AIM of the London Stock Exchange. Revenue increased from £12 to c.£49m over his tenure and he raised £107m through equity issues and €40m through debt finance to fund over 15 clinical studies.

Prior to this he worked for Ellerman Investments (1997-2002), a UK private equity house, undertaking the roles of Chief Executive Officer with AFS, which was one of the largest independent finance houses in the UK, raising over £400m in debt finance, and Finance Director with a number of successful start-up technology companies. Previously he held senior finance positions with Ericsson and Philips Electronics.

He is also a non-executive director and Deputy Chairman of Shoreham Port. He is a Fellow of the Chartered Association of Certified Accountants and has a BSc (Hons) in Geological Sciences from Aston University.

The Company’s ordinary shares are admitted to trading on AIM. There are no other exchanges or trading platforms on which the Company has applied or agreed to have any of its securities (including its AIM securities) admitted or traded.

There are no restrictions on the transfer of the Company’s ordinary shares.

The Company is subject to the UK City Code on Takeovers and Mergers.

As at 31 August 2018, the Company’s issued share capital consists of 78,561,866 ordinary shares of 5p and the following interests of shareholders in excess of 3 per cent have been notified to the Company:

Shareholder Number of Shares Percentage
Woodford Investment Management 36,787,187 46.83%
Invesco Asset Management 15,536,967 19.78%
Cyrus Holdings Limited 10,389,520 13.22%
JO Hambro 6,544,523 8.33%
Hargreaves Lansdown Ltd HLNOM Account 3,892,905 4.96%

 

A total of 80% of the issued share capital is not in public hands as defined for Rule 26 purposes being directors, management and those shareholders holding more than 10% of the issued share capital.

NetScientific plc
1st floor, Bury Court
6 Bevis Marks
London
EC3A 7BA

Tel: +44 20 3514 1800
Call: +44 20 3514 1800

[email protected]

Nominated Adviser and Broker: WH Ireland Limited 24 Martin Lane London EC4R 0DR
Solicitors: UK:     Ashurst LLP  Broadwalk House  5 Appold Street London EC2A 2HA

 

USA:  DLA Piper LLP  One Liberty Place  1650 Market Street Suite 4900 Philadelphia  Pennsylvania 19103-7300  USA

Independent Auditors: BDO LLP Arcadia House Maritime Walk Ocean Village Southampton Hampshire SO14 3TL
Reporting Accountants: BDO LLP 55 Baker Street London W1U 7EU
Registrar: Link Asset Services The Registry 34 Beckenham Road Beckenham Kent BR3 4TU
Public Relations: Consilium Strategic Communications  41 Lothbury London EC2R 7HG

 

Columns Including NSCI

VIEW ALL

Market Reports Including NSCI

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use